Organogenesis Holdings Inc Total Liabilities
Organogenesis Holdings Inc total liabilities. Based on the latest financial reports, Organogenesis Holdings Inc (ORGO) has total liabilities worth $123.85 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See defensive interval ratio of Organogenesis Holdings Inc to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Organogenesis Holdings Inc (2001–2024)
Total liabilities of Organogenesis Holdings Inc from 2001 to 2024. This chart illustrates how Organogenesis Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Organogenesis Holdings Inc's assets to evaluate the company's liquid asset resilience ratio.
Organogenesis Holdings Inc Competitors by Total Liabilities
The table below lists competitors of Organogenesis Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CF Acquisition VII Corp
NASDAQ:CFFS
|
USA | $12.74 Million |
|
Dhampur Sugar Mills Limited
NSE:DHAMPURSUG
|
India | Rs12.17 Billion |
|
Bhiraj Office Leasehold Real Estate Investment Trust
BK:BOFFICE
|
Thailand | ฿2.56 Billion |
|
CONDOR ENERGIES INC.
F:WQ6
|
Germany | €76.61 Million |
|
Apollo Food Holdings Bhd
KLSE:6432
|
Malaysia | RM23.53 Million |
|
Magyar Bancorp Inc
NASDAQ:MGYR
|
USA | $923.75 Million |
|
Chongkundang
KO:001630
|
Korea | ₩814.73 Billion |
|
The Platinum Group Public Company Limited
BK:PLAT
|
Thailand | ฿4.40 Billion |
Liability Composition Analysis (2001–2024)
This chart breaks down Organogenesis Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ORGO asset base.
Liquidity & Leverage Metrics
Organogenesis Holdings Inc Total Liabilities Ratios Explained
Organogenesis Holdings Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Organogenesis Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Organogenesis Holdings Inc (2001–2024)
The table below shows the annual total liabilities of Organogenesis Holdings Inc from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $112.57 Million | -37.93% |
| 2023-12-31 | $181.36 Million | -1.27% |
| 2022-12-31 | $183.69 Million | -9.03% |
| 2021-12-31 | $201.92 Million | +36.06% |
| 2020-12-31 | $148.41 Million | -10.11% |
| 2019-12-31 | $165.10 Million | +41.55% |
| 2018-12-31 | $116.64 Million | +689.22% |
| 2017-12-31 | $14.78 Million | +30.46% |
| 2016-12-31 | $11.33 Million | +2620.33% |
| 2015-12-31 | $416.43K | -91.14% |
| 2001-12-31 | $4.70 Million | -- |
About Organogenesis Holdings Inc
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barrier… Read more